In the search for new therapeutic approaches for RTT, antidepressants have been considered, based on the evidence of reduced brain levels of the monoamines serotonin (5‐HT), noradrenaline (NA), and dopamine (DA) in RTT patients and Mecp2‐KO mouse models in which the gene responsible for RTT was deleted (Samaco et al. 2009; Temudo et al. 2009). Here, MECP2 is linked to Rett syndrome.